Thanks again Enumerate, and agree on the drivers of value.In the...

Thanks again Enumerate, and agree on the drivers of value.

In the near term a 'deal' with Janssen would benefit as it would help build mgt credibility, even if it's not the most lucrative financially. It would also help to independently validate the science, which so far has only been done by PYC itself.

The drivers you describe are of course much more significant in terms of valuations, but are also unfortunately much more long-term and much less controllable by PYC, i.e. we seem to be at the mercy of pharma/Janssen - and their agenda is very much their own, as one would expect.

In this regards the "when" question is a bit like 'how long is a piece of string'. No real answer..., but in the meantime we are being asked to 'trust' management, who's credibility has suffered, and hence we circle back to delivering on promises such as Janssen.

Call me old fashioned, but I prefer to trust people that do what they say they will.